Product Description
Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34430790/)
Mechanisms of Action: FVII Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: Fast Track - Factor V Deficiency|Factor VII Deficiency|Injuries/wounds UnspecifiedFast Track - Hemophilia A|Injuries/wounds UnspecifiedOrphan Drug - Factor V Deficiency|Factor VII Deficiency *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Catalyst Biosciences
Company Location: CORAL GABLES FL 33134
Company CEO: Patrick J. McEnany
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hemophilia A|Hemophilia B|Injuries/wounds Unspecified
Phase 2: Factor VII Deficiency|Hemophilia A|Hemostatic Disorders|Blood Coagulation Disorders|Factor V Deficiency|Thrombasthenia
Phase 1: Hemophilia A|Hemophilia B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MAA-202 | P2 |
Terminated |
Factor V Deficiency|Hemophilia A|Thrombasthenia|Factor VII Deficiency |
2022-09-30 |
|
| The Crimson 1 Study | P3 |
Terminated |
Hemophilia B|Hemophilia A |
2021-11-15 |
72% |
| MAA-202 | P2 |
Terminated |
Factor VII Deficiency|Hemostatic Disorders|Thrombasthenia|Blood Coagulation Disorders|Hemophilia A|Factor V Deficiency |
2021-11-15 |
24% |
| MAA-102 | P1 |
Completed |
Hemophilia A|Hemophilia B |
2020-04-30 |